Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Boston Scientific Announces Results For Second Quarter 2018

      Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

      News provided by

      Boston Scientific Corporation

      Jul 25, 2018, 06:30 ET

      Share this article

      Share this article


      MARLBOROUGH, Mass., July 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.490 billion during the second quarter ended June 30, 2018. This represents growth of 10.3 percent on a reported basis, 8.6 percent on an operational1 basis and 7.9 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP earnings of $555 million or $0.40 per share (EPS), compared to GAAP earnings of $146 million or $0.11 per share a year ago, and achieved adjusted earnings per share of $0.41 for the period, compared to $0.32 a year ago.

      "Our strong sales and EPS growth in the second quarter were fueled by our global team, robust portfolio and diversified business," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We're committed to advancing science for life, and we're excited about the ways our differentiated pipeline will continue to drive our growth and impact on patients, physicians and hospital systems."

      Second quarter financial results and recent developments:

      • Reported second quarter sales of $2.490 billion, compared to the company's guidance range of $2.450 to $2.500 billion, representing an increase of 10.3 percent on a reported basis, 8.6 percent on an operational basis and 7.9 percent on an organic basis, all compared to the prior year period.
                                                                                       
      • Reported GAAP earnings of $0.40 per share compared to the company's guidance range of $0.21 to $0.23 per share, which includes a $250 million non-cash benefit from finalizing the company's IRS tax settlement. Achieved adjusted earnings per share of $0.41 compared to the guidance range of $0.33 to $0.35 per share, which includes a $82 million non-cash benefit from finalizing the aforementioned settlement.
                                                                                       
      • Achieved second quarter revenue growth in all segments, compared to the prior year period:
        • MedSurg: 10.4 percent reported, 9.0 percent operational and organic
        • Rhythm and Neuro: 10.8 percent reported, 9.0 percent operational and organic
        • Cardiovascular: 10.0 percent reported, 8.0 percent operational and 6.2 percent organic
                                                                                         
      • Delivered revenue growth in all regions, compared to the prior year period:
        • U.S.: 7.9 percent reported, operational and organic
        • EMEA (Europe, Middle East and Africa): 15.8 percent reported, 9.6 percent operational and 6.6 percent organic
        • APAC (Asia-Pacific): 12.3 percent reported, 8.7 percent operational and organic
        • Emerging Markets3: 22.0 percent reported, 21.1 percent operational and 20.6 percent organic
                                                                                         
      • Presented two-year real-world data (RESPOND) at the annual EuroPCR Scientific Program, demonstrating favorable clinical outcomes in patients treated with the LOTUS™ Transcatheter Aortic Valve System,4 in addition to sub-analysis from the REPRISE III trial, where the LOTUS Valve system showed significantly lower disabling stroke rate versus CoreValve® (Medtronic).
                                                                                       
      • Announced real-world data at the Heart Rhythm Society's 39th Annual Scientific Sessions, demonstrating the successful reduction of inappropriate shocks using the SMART Pass sensing filter in patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System.
                                                                                       
      • Received U.S. Food and Drug Administration (FDA) approval, CE Mark and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the ROTAPRO™ Rotational Atherectomy System, a next-generation rotational atherectomy technology used to debulk and modify calcified plaques from coronary arteries prior to stent implantation to achieve optimal results.
                                                                                       
      • Secured expanded indication for the Embozene™ Microspheres to treat symptomatic benign prostatic hyperplasia (BPH), a procedure which was recently supported by the U.K. National Institute for Health and Care Excellence (NICE).
                                                                                       
      • Closed the acquisition of Cryterion Medical, Inc., a privately-held company developing a single-shot cryoablation balloon for the treatment of atrial fibrillation (AF), positioning Boston Scientific to be the first company to have both cryothermal and radiofrequency single-shot, balloon-based pulmonary vein ablation therapies in its portfolio.
                                                                                       
      • Closed the acquisition of NxThera, Inc., a privately-held company that developed the Rezûm® system, a minimally invasive therapy (MIT) and office-based treatment for patients with symptomatic BPH.
                                                                                       
      • Announced an agreement to acquire Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel® Cerebral Embolic Protection System, used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR).

      1. Operational revenue growth excludes the impact of foreign currency fluctuations. 
      2. Organic revenue growth excludes the impact of foreign currency fluctuations and sales from the acquisition of Symetis SA with no prior period related net sales. 
      3. We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets. 
      4. The LOTUS Valve system is currently not available for use or sale.

      Net sales for the second quarter by business and region:






      Change



      Three Months Ended
      June 30,


      Reported Basis


      Less: Impact
      of Foreign
      Currency
      Fluctuations


      Operational
       Basis


      Less:

      Impact of
      Significant
      Acquisitions


      Organic Basis

      (in millions)

      2018

      2017







         Endoscopy

      $

      442


      $

      400



      10.6%


      1.7%


      8.9%


      —%


      8.9%


         Urology and Pelvic Health

      308


      280



      10.1%


      1.0%


      9.1%


      —%


      9.1%


      MedSurg*

      751


      680



      10.4%


      1.4%


      9.0%


      —%


      9.0%


         Cardiac Rhythm Management

      494


      480



      3.0%


      1.8%


      1.2%


      —%


      1.2%


         Electrophysiology

      79


      67



      18.5%


      2.7%


      15.8%


      —%


      15.8%


         Neuromodulation

      202


      154



      31.5%


      0.9%


      30.6%


      —%


      30.6%


      Rhythm and Neuro*

      775


      700



      10.8%


      1.8%


      9.0%


      —%


      9.0%


         Interventional Cardiology

      662


      603



      9.6%


      2.0%


      7.6%


      2.5%


      5.1%


         Peripheral Interventions

      304


      273



      10.8%


      2.1%


      8.7%


      —%


      8.7%


      Cardiovascular

      965


      876



      10.0%


      2.0%


      8.0%


      1.8%


      6.2%















      Net Sales

      $

      2,490


      $

      2,257



      10.3%


      1.7%


      8.6%


      0.7%


      7.9%
















      *Prior period segment amounts revised in accordance with ASC 280, Segment Reporting, to reflect the reclassification of Neuromodulation from the MedSurg segment to the Rhythm and Neuro segment, effective January 1, 2018.






      Change



      Three Months Ended
      June 30,


      Reported Basis


      Less: Impact
      of Foreign
      Currency
      Fluctuations


      Operational
       Basis


      Less:
      Impact of
      Significant
      Acquisitions


      Organic Basis

      (in millions)

      2018

      2017





















      U.S.

      $

      1,394


      $

      1,291



      7.9%


      —%


      7.9%


      —%


      7.9%


      EMEA**

      558


      482



      15.8%


      6.2%


      9.6%


      3.0%


      6.6%


      APAC**

      442


      393



      12.3%


      3.6%


      8.7%


      —%


      8.7%


      Latin America and Canada

      96


      90



      7.6%


      (5.2)%


      12.8%


      1.0%


      11.8%
















      Net Sales

      $

      2,490


      $

      2,257



      10.3%


      1.7%


      8.6%


      0.7%


      7.9%
















      Emerging Markets

      $

      276


      $

      226



      22.0%


      0.9%


      21.1%


      0.5%


      20.6%
















      **Regional totals reflect the reclassification of Middle East and Africa from the former AMEA region to Europe, effective January 1, 2018.


      Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.


      Sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of recent acquisitions with significant sales are not prepared in accordance with U.S. GAAP.















      Guidance for Full Year and Third Quarter 2018

      The company now estimates revenue for the full year 2018 to be in a range of $9.800 to $9.880 billion (compared to prior guidance of $9.750 to $9.900 billion), which versus the prior year period represents a growth range of approximately 8 to 9 percent on a reported basis and growth of approximately 6 to 7 percent on an organic basis excluding the impact of foreign currency fluctuations and contribution of approximately 40 basis points from acquisitions. The company now estimates income on a GAAP basis in a range of $0.99 to $1.03 per share (compared to prior guidance of $0.90 to $0.94 per share) and estimates adjusted earnings, excluding amortization expense, intangible asset impairment charges, acquisition-related net charges (credits), restructuring and restructuring-related net charges (credits), certain investment impairments and certain discrete tax items, in a range of $1.37 to $1.41 per share (compared to prior guidance of $1.37 to $1.41 per share).

      The company estimates sales for the third quarter of 2018 to be in a range of $2.380 to $2.420 billion, which versus the prior year period represents a growth range of approximately 7 to 9 percent on a reported basis and a growth range of approximately 7 to 8 percent on an organic basis, excluding the impact of foreign currency fluctuations. The company estimates earnings on a GAAP basis in a range of $0.21 to $0.23 per share and adjusted earnings, excluding amortization expense, acquisition-related net charges (credits) and restructuring and restructuring-related net charges (credits), in a range of $0.33 to $0.35 per share.

      Conference Call Information

      Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. EDT. The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

      About Boston Scientific 
      Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

      Cautionary Statement Regarding Forward-Looking Statements 
      This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," "aiming" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, GAAP earnings and adjusted earnings for the third quarter and full year 2018, our financial performance, our business plans and our positioning for revenue and earnings growth. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

      Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions, new product introductions and the market acceptance of those products, markets for our products, expected pricing environment, expected procedural volumes, the closing and integration of acquisitions, clinical trial results, demographic trends, intellectual property rights, litigation, financial market conditions, the execution and effect of our restructuring program, the execution and effect of our business strategy, including our cost-savings and growth initiatives and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

      Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Prior year balances were subject to rounding.

      Use of Non-GAAP Financial Information 
      A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

      CONTACT:





          Media:

      Kate Haranis


      Investors:

      Susie Lisa, CFA


      508-683-6585 (office)



      508-683-5565 (office)


      Media Relations



      Investor Relations


      Boston Scientific Corporation



      Boston Scientific Corporation


      [email protected]



      [email protected]


      BOSTON SCIENTIFIC CORPORATION

      CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

      (Unaudited)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      in millions, except per share data

      2018

      2017


      2018

      2017







      Net sales

      $

      2,490


      $

      2,257



      $

      4,870


      $

      4,418


      Cost of products sold

      739


      632



      1,411


      1,282


      Gross profit

      1,751


      1,625



      3,458


      3,136








      Operating expenses:






      Selling, general and administrative expenses

      886


      815



      1,746


      1,609


      Research and development expenses

      275


      244



      536


      480


      Royalty expense

      17


      17



      35


      34


      Amortization expense

      147


      142



      288


      285


      Intangible asset impairment charges

      34


      —



      35


      —


      Contingent consideration expense (benefit)

      (4)


      (24)



      1


      (74)


      Restructuring charges (credits)

      5


      1



      18


      5


      Litigation-related net charges (credits)

      —


      205



      —


      208



      1,359


      1,400



      2,659


      2,547


      Operating income (loss)

      392


      225



      799


      589








      Other income (expense):






      Interest expense

      (57)


      (58)



      (119)


      (115)


      Other, net

      12


      (76)



      (11)


      (78)


      Income (loss) before income taxes

      347


      91



      670


      396


      Income tax expense (benefit)

      (209)


      (55)



      (183)


      (40)


      Net income (loss)

      $

      555


      $

      146



      $

      853


      $

      436








      Net income (loss) per common share - basic

      $

      0.40


      $

      0.11



      $

      0.62


      0.32


      Net income (loss) per common share - assuming dilution

      $

      0.40


      $

      0.11



      $

      0.61


      0.31








      Weighted-average shares outstanding






      Basic

      1,380.5


      1,369.8



      1,378.5


      1,367.6


      Assuming dilution

      1,398.9


      1,391.1



      1,397.8


      1,390.6


      BOSTON SCIENTIFIC CORPORATION

      NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

      (Unaudited)




      Three Months Ended June 30, 2018

      in millions, except per share data


      Cost of
      Products
      Sold


      SG&A
      Expenses


      R&D
      Expenses


      Operating
      Income
      (Loss)


      Pre-Tax
      Income
      (Loss)


      Net
      Income
      (Loss)


      Impact
      per
      Share

      GAAP net income (loss)


      $

      739



      $

      886



      $

      275



      $

      392



      $

      347



      $

      555



      $

      0.40


      Non-GAAP adjustments:















      Amortization expense


      —



      —



      —



      147



      147



      130



      0.09


      Intangible asset impairment charges


      —



      —



      —



      34



      34



      30



      0.02


      Acquisition-related net charges (credits)


      (9)



      (27)



      (15)



      46



      5



      9



      0.01


      Restructuring and restructuring-related net charges (credits)


      (16)



      5



      —



      15



      15



      13



      0.01


      Discrete tax items


      —



      —



      —



      —



      —



      (168)



      (0.12)


      Adjusted net income


      $

      715



      $

      865



      $

      260



      $

      633



      $

      547



      $

      568



      $

      0.41



















      Three Months Ended June 30, 2017

      in millions, except per share data


      Cost of
      Products
      Sold


      SG&A
      Expenses


      R&D
      Expenses


      Operating
      Income
      (Loss)


      Pre-Tax
      Income
      (Loss)


      Net
      Income
      (Loss)


      Impact
      per
      Share

      GAAP net income (loss)


      $

      632



      $

      815



      $

      244



      $

      225



      $

      91



      $

      146



      $

      0.11


      Non-GAAP adjustments:















      Amortization expense


      —



      —



      —



      142



      142



      121



      0.09


      Acquisition-related net charges (credits)


      (7)



      (11)



      (5)



      (1)



      8



      (1)



      0.00


      Restructuring and restructuring-related net charges (credits)


      (12)



      (3)



      —



      16



      16



      13



      0.01


      Litigation-related net charges (credits)


      —



      —



      —



      205



      205



      131



      0.09


      Investment impairment charges


      —



      —



      —



      —



      53



      34



      0.02


      Adjusted net income


      $

      613



      $

      801



      $

      239



      $

      587



      $

      515



      $

      444



      $

      0.32
































      An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

      BOSTON SCIENTIFIC CORPORATION

      NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

      (Unaudited)




      Six Months Ended June 30, 2018

      in millions, except per share data


      Cost of
      Products
      Sold


      SG&A
      Expenses


      R&D
      Expenses


      Operating
      Income
      (Loss)


      Pre-Tax
      Income
      (Loss)


      Net
      Income
      (Loss)


      Impact
      per
      Share

      GAAP net income (loss)


      $

      1,411



      $

      1,746



      $

      536



      $

      799



      $

      670



      $

      853



      $

      0.61


      Non-GAAP adjustments:















      Amortization expense


      —



      —



      —



      288



      288



      248



      0.18


      Intangible asset impairment charges


      —



      —



      —



      35



      35



      31



      0.02


      Acquisition-related net charges (credits)


      (15)



      (33)



      (22)



      71



      30



      29



      0.02


      Restructuring and restructuring-related net charges (credits)


      (23)



      (3)



      —



      43



      43



      35



      0.02


      Investment impairment charges


      —



      —



      —



      —



      5



      5



      0.00


      Discrete tax items


      —



      —



      —



      —



      —



      (177)



      (0.13)


      Adjusted net income


      $

      1,374



      $

      1,710



      $

      514



      $

      1,237



      $

      1,071



      $

      1,023



      $

      0.73



















      Six Months Ended June 30, 2017

      in millions, except per share data


      Cost of
      Products
      Sold


      SG&A
      Expenses


      R&D
      Expenses


      Operating
      Income
      (Loss)


      Pre-Tax
      Income
      (Loss)


      Net
      Income
      (Loss)


      Impact
      per
      Share

      GAAP net income (loss)


      $

      1,282



      $

      1,609



      $

      480



      $

      589



      $

      396



      $

      436



      $

      0.31


      Non-GAAP adjustments:















      Amortization expense


      —



      —



      —



      285



      285



      243



      0.17


      Acquisition-related net charges (credits)


      (10)



      (22)



      (9)



      (33)



      (24)



      (33)



      (0.02)


      Restructuring and restructuring-related net charges (credits)


      (24)



      (6)



      —



      35



      35



      28



      0.02


      Litigation-related net credits (credits)


      —



      —



      —



      208



      208



      133



      0.10


      Investment impairment charges


      —



      —



      —



      —



      53



      34



      0.02


      Adjusted net income


      $

      1,248



      $

      1,581



      $

      471



      $

      1,084



      $

      953



      $

      841



      $

      0.60
































      An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

      BOSTON SCIENTIFIC CORPORATION

      ESTIMATED REVENUE NON-GAAP GROWTH RATES AND NON-GAAP NET INCOME PER SHARE RECONCILIATIONS

      (Unaudited)


      Q3 and Full Year 2018 Estimated Revenue Growth Rates



      Q3 2018 Estimate


      Full Year 2018
      Estimate


      Prior Full Year
      2018 Estimate


      (Low)

      (High)


      (Low)

      (High)


      (Low)

      (High)

      Estimated GAAP sales growth

      7%

      9%


      8%

      9%


      8%

      10%

      Less: Estimated impact of foreign currency
      fluctuations and significant acquisitions

      0%

      1%


      2%

      2%


      3%

      3%

      Estimated sales growth, organic*

      7%

      8%


      6%

      7%


      5%

      7%










      *Full Year 2018 Estimates excludes contribution of approximately 40 basis points from acquisitions.

       

       

      Q3 and Full Year 2018 Earnings per Share Guidance


      Q3 2018 Estimate


      Full Year 2018
      Estimate


      Prior Full Year
      2018 Estimate


      (Low)

      (High)


      (Low)

      (High)


      (Low)

      (High)

      GAAP results

      $

      0.21


      $

      0.23



      $

      0.99


      $

      1.03



      $

      0.90


      $

      0.94











      Estimated amortization expense

      0.08


      0.08



      0.36


      0.36



      0.35


      0.35


      Intangible asset impairment charges

      —


      —



      0.02


      0.02



      0.00


      0.00


      Estimated acquisition-related net charges (credits)

      0.02


      0.02



      0.05


      0.05



      0.05


      0.05


      Estimated restructuring and restructuring-related net charges
      (credits)

      0.02


      0.02



      0.08


      0.08



      0.08


      0.08


      Investment impairment charges

      —


      —



      0.00


      0.00



      0.00


      0.00


      Discrete tax items

      —


      —



      (0.13)


      (0.13)



      (0.01)


      (0.01)











      Adjusted results

      $

      0.33


      $

      0.35



      $

      1.37


      $

      1.41



      $

      1.37


      $

      1.41











      Prior Guidance Estimate - Q2 2018 Earnings per Share

       


      Q2 2018 Estimate


      (Low)

      (High)

      GAAP results

      $

      0.21


      $

      0.23





      Estimated amortization expense

      0.08


      0.08


      Estimated acquisition-related net charges (credits)

      0.02


      0.02


      Estimated restructuring and restructuring-related net charges (credits)

      0.02


      0.02





      Adjusted results

      $

      0.33


      $

      0.35





      Use of Non-GAAP Financial Measures

      To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts, operational net sales, which exclude the impact of foreign currency fluctuations and organic net sales, which exclude the impact of foreign currency fluctuations and the impact of recent acquisitions with significant sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

      To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income, including amortization expense, intangible asset impairment charges, acquisition-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment charges and certain discrete tax items, as described below. Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type that management excluded as part of these non-GAAP financial measures, since our most recent Annual Report on Form 10-K, as well as the reason for excluding each individual item:

      • Discrete tax items — These items represent adjustments of certain tax positions including those which a) are estimates as a result of the TCJA, enacted in December 2017, and, or b) were a benefit resulting from the finalization of the IRS Stipulation of Settled Issues consistent with the manner in which the tax reserves were originally booked. These adjustments are not indicative of expected on-going operating results. We exclude the impact of this charge from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these amounts for the purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

      The GAAP financial measures most directly comparable to adjusted net income and adjusted net income per share are GAAP net income and GAAP net income per share.

      To calculate operational net sales, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. To calculate organic net sales, we remove the impact of recent acquisitions with significant sales from operational net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

      Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

      Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. With the exception of the impact of recent acquisitions with significant sales, the adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

      We believe that presenting adjusted net income and adjusted net income per share, operational net sales and organic net sales, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

      SOURCE Boston Scientific Corporation

      Modal title

      Also from this source

      SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

      Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial...

      Boston Scientific announces results for third quarter 2026

      Boston Scientific announces results for third quarter 2026

      Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.